NEW YORK (GenomeWeb) – Biotech firm MeMed today announced it has been awarded a $9.2 million contract to complete the development of its point-of-care platform for distinguishing bacterial from viral infections.

The grant is from the Defense Threat Reduction Agency, a branch of the US Department of Defense. In collaboration with researchers and clinicians, the firm has spent the past eight years studying changes in the human immune system when it fights infections, in order to develop a human immune signature that recognizes the difference between bacterial and viral infections.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.